02 December 2021 - Article
Collaboration Agreement combining the unique capabilities of our client, Elasmogen’s soloMER™ technology with those of Feldan’s Shuttle platform to develop the delivery system and binding domains for two undisclosed intracellular targets for Amgen.
Collaboration Agreement between Parkinson’s UK and Sheffield University to create new treatments for Parkinson’s disease.
Research and development agreement between Scotia Biologics and TC BioPharm for use of Scotia’s antibodies in TC BioPharm;s CAR-T treatment platform.
Collaboration Agreement between Mologic Limited and Cardiff University for the development and commercialisation of point-of-care diagnostic for home use as an aid to diagnosis of infection in patients receiving Peritoneal Dialysis treatment.
Accelerator Services Agreement for Health Enterprise East to launch Medovate to develop and commercialise innovative medical technologies from within the NHS.
Advised Malaysian based oncology company on licence, development and supply agreement with a Cuban government research organisation in relation to lung cancer vaccine. Advised on the development and clinical milestone payments, commercialisation and royalty payments and sublicensing revenues.
Advised a UK based biotech on an exclusive technology licensing agreement with a leading UK university under which the university licensed its technology (novel antibiotics to control certain bacterial infections in vivo). Advised on the development milestone payments and royalties
Advised a UK based international pharmaceutical company on a co-development agreement with a US multinational pharmaceutical company for the development and approval of a Leukaemia drug. Advice included drafting of development cost, earn-out and net sales milestone provisions.
Advised and drafted licence and research agreements for the use of animal cell lines to develop and commercialise clean meat products.
England and Wales, 2009
PLC - Negotiating multi-jurisdictional clinical trial agreements
PLC - Regulatory and IP due diligence checklist: Pharmaceutical and biotechnology (to be published later this year)
Speaker at the Boston Bar Association conference 2017
Speaker at BDO UK IP seminar